

## Offene Studien

Eudara-CT Sponsor	Studienbezeichnung	Phase Status	PI
NCT02622581 AIO- Studien-gGmbH	AIO-TRK-0315: Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients (CRISP)	IV offen	Wiegand
EUDRACT 2022-000493-26 Parexel / Astra	A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti PD (L)1 Therapy and Platinum-based Chemotherapy: LATIFY (D533BC00001)	III geschlossen	Kambartel Voshaar Yildirim
EUDRACT 2021-004327-32 Astra	A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8)	III offen	Kambartel Voshaar Yildirim
EUDRACT 2023-503357-35-00 Astra	A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC) ("MDTBridge")	II in Planung	Kambartel Yildirim
NCT05538806 Novocure	Studie zur Anwendung von TTFIELDS in der klinischen Routine bei Patientinnen und Patienten mit einem Pleuramesotheliom, (TIGER Meso Studie)	II offen	Kambartel Möller
EUDRACT 2023-503376-24-00 MSD	A Phase 3 Study of MK-2870 in Combination with Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line-Treatment of Participants with Metastatic Non-small-cell-Lung Cancer with PD-L1 TPS $\geq$ 50% MSD 2870-007 MSD 2870-007)	III Start 05/24 geplant	Kambartel
Revolution Medicines	Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C Mutant Solid Tumors	Ib in Planung	Kambartel Yildirim
EUDRACT 2023-507448-36-00	A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in Subjects with Metastatic Non-squamous Non-small Cell Lung Cancer "Samsung Bioepis"	III offen	Kambartel Möller